AtomVie Global Radiopharma builds radiopharmaceutical CDMO facility in Hamilton
by CM staff
The facility will include cleanrooms and laboratories to sustain over 18 production lines and space for dedicated, high-volume commercial manufacturing.
AtomVie’s new facility at 10 Aeropark Blvd, Hamilton, Ontario – credit of Panattoni Development Company. (CNW Group/AtomVie Global Radiopharma Inc.)
TORONTO — AtomVie Global Radiopharma Inc., (AtomVie) announced the execution of a lease agreement with Panattoni Development Company in Hamilton, Ont., for its new facility.
The facility will be dedicated to high volume clinical and commercial GMP manufacturing and worldwide distribution of radiotherapeutics, a high-growth class of drugs for the treatment of cancer patients.
Currently located on the McMaster University campus, AtomVie operates a global leading Contract Development and Manufacturing Organization (CDMO) facility that is home for over 10 international radiopharmaceutical GMP manufacturing programs. The new facility of 64,000 square feet, is expected to be commissioned in 2024 and will increase production capacity by 10X, allowing the expansion of its clinical and commercial operations to meet the needs of the expanding radiopharmaceutical market.
“AtomVie celebrates yet another milestone by beginning a buildout that will increase our capacity more than ten-fold” says Bruno Paquin, CEO of AtomVie Global Radiopharma.”We are thrilled to continue being part of the Hamilton radiopharmaceutical ecosystem and by partnering with Panattoni, we were able to choose our new facility’s home to meet clinical and commercial supply needs for radiotherapeutics, resulting in patients receiving much-needed therapies.”
